IL316019A - Combined treatment for cancer - Google Patents

Combined treatment for cancer

Info

Publication number
IL316019A
IL316019A IL316019A IL31601924A IL316019A IL 316019 A IL316019 A IL 316019A IL 316019 A IL316019 A IL 316019A IL 31601924 A IL31601924 A IL 31601924A IL 316019 A IL316019 A IL 316019A
Authority
IL
Israel
Prior art keywords
combination therapy
treating cancer
cancer
treating
therapy
Prior art date
Application number
IL316019A
Other languages
English (en)
Hebrew (he)
Inventor
Sabina Chiara Cosulich
Jessica S Brown
Mark R Albertella
Elisabetta Leo
Original Assignee
Astrazeneca Ab
Sabina Chiara Cosulich
Jessica S Brown
Mark R Albertella
Elisabetta Leo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Sabina Chiara Cosulich, Jessica S Brown, Mark R Albertella, Elisabetta Leo filed Critical Astrazeneca Ab
Publication of IL316019A publication Critical patent/IL316019A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
IL316019A 2022-04-07 2023-04-06 Combined treatment for cancer IL316019A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263362614P 2022-04-07 2022-04-07
PCT/EP2023/059123 WO2023194525A1 (en) 2022-04-07 2023-04-06 Combination therapy for treating cancer

Publications (1)

Publication Number Publication Date
IL316019A true IL316019A (en) 2024-11-01

Family

ID=86184958

Family Applications (1)

Application Number Title Priority Date Filing Date
IL316019A IL316019A (en) 2022-04-07 2023-04-06 Combined treatment for cancer

Country Status (11)

Country Link
US (1) US20250228847A1 (enExample)
EP (1) EP4504147A1 (enExample)
JP (1) JP2025511403A (enExample)
KR (1) KR20240170958A (enExample)
CN (1) CN118973555A (enExample)
AU (1) AU2023250030A1 (enExample)
CA (1) CA3254950A1 (enExample)
IL (1) IL316019A (enExample)
MX (1) MX2024012369A (enExample)
TW (1) TW202404592A (enExample)
WO (1) WO2023194525A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240325384A1 (en) * 2023-03-31 2024-10-03 Astrazeneca Ab Dosing regimen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0699754B2 (en) 1994-08-12 2009-08-12 The University of Utah Research Foundation Method for diagnosing a predisposition for breast and ovarian cancer
DE69521002T3 (de) 1994-08-12 2010-02-25 The University Of Utah Research Foundation, Salt Lake City Mutationen des mit 17q verbundenen Ovarial- und Brustkrebs Empfindlichkeitsgens
EA201992430A1 (ru) * 2017-04-13 2020-02-28 Янссен Фармацевтика Нв Комбинированная терапия рака предстательной железы
TWI837403B (zh) 2019-07-19 2024-04-01 瑞典商阿斯特捷利康公司 化學化合物
TW202228693A (zh) * 2020-10-08 2022-08-01 瑞典商阿斯特捷利康公司 用於治療癌症之組合療法

Also Published As

Publication number Publication date
CN118973555A (zh) 2024-11-15
CA3254950A1 (en) 2023-10-12
KR20240170958A (ko) 2024-12-05
JP2025511403A (ja) 2025-04-15
MX2024012369A (es) 2024-11-08
AU2023250030A1 (en) 2024-11-07
EP4504147A1 (en) 2025-02-12
US20250228847A1 (en) 2025-07-17
TW202404592A (zh) 2024-02-01
WO2023194525A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
IL304275A (en) Cancer treatment methods
PT4225297T (pt) Terapia de combinação para o tratamento de cancro
IL307964A (en) Combined treatment for cancer
IL320332A (en) Cancer treatment methods
ZA202310076B (en) Combination therapies for treating cancer
IL319513A (en) Compounds for cancer treatment
IL316017A (en) Combined treatment for cancer
IL316016A (en) Combined treatment for cancer
IL317573A (en) Combination therapy for cancer treatment
GB202301902D0 (en) Combination therapy for cancer
IL288178A (en) Combined gmci and ddri treatment for cancer
GB202218395D0 (en) Cancer therapy
EP4313029A4 (en) COMBINATION THERAPY FOR CANCER TREATMENT
IL305777A (en) Medical combination for cancer treatment
IL326216A (en) Combination therapy for treating prostate cancer
CA3272243A1 (en) Combination therapy for treating cancer
HK40121856A (en) Combination therapy for treating cancer
HK40121918A (en) Combination therapy for treating cancer
GB202208893D0 (en) Combination therapy for cancer
IL317472A (en) Arbecycline for cancer treatment
HK40107047A (en) Therapeutic combination for treating cancer
IL320482A (en) Combination therapy for cancer treatment
GB202508616D0 (en) Combination therapy for cancer
CA3302004A1 (en) Combination therapy for treating prostate cancer
CA3307092A1 (en) Combination therapy for cancer treatment